BioStock: Targinta’s CEO comments on preclinical data in TNBC and the spin-out
The oncology company Targinta recently presented new preclinical data on TARG10 at the AACR Annual Meeting. The results show that the cell surface marker integrin α10β1 is selectively expressed in aggressive forms of triple-negative breast cancer (TNBC) and that TARG10 inhibits metastasis of TNBC. BioStock contacted Targinta’s CEO Per Norlén to find out more about the preclinical results, and why the spin-out from the parent company Xintela is now being postponed.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se